X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (908) 908
male (686) 686
female (622) 622
index medicus (595) 595
gastroenterology & hepatology (590) 590
middle aged (570) 570
aged (476) 476
adult (403) 403
aged, 80 and over (202) 202
oncology (173) 173
retrospective studies (163) 163
cancer (160) 160
treatment outcome (160) 160
gastroenterology (154) 154
hepatitis c virus (152) 152
infection (145) 145
medicine & public health (145) 145
analysis (136) 136
hepatology (136) 136
risk factors (129) 129
interferon (128) 128
animals (127) 127
hepatocellular carcinoma (122) 122
japan (116) 116
health aspects (115) 115
hepatitis c (113) 113
care and treatment (112) 112
genotype (112) 112
hepacivirus - genetics (112) 112
prognosis (112) 112
liver (110) 110
antiviral agents - therapeutic use (101) 101
mice (100) 100
surgery (98) 98
ribavirin (97) 97
hepatitis c, chronic - drug therapy (94) 94
hepatitis (92) 92
diagnosis (91) 91
surgical oncology (90) 90
cirrhosis (88) 88
gastroenterology and hepatology (88) 88
virology (86) 86
colorectal surgery (84) 84
tumors (84) 84
helicobacter pylori (82) 82
expression (81) 81
risk (80) 80
carcinoma (78) 78
genetic aspects (78) 78
therapy (78) 78
disease (75) 75
follow-up studies (75) 75
cardiac & cardiovascular systems (73) 73
multivariate analysis (73) 73
hepatocellular-carcinoma (71) 71
time factors (71) 71
liver cirrhosis (70) 70
mutation (70) 70
young adult (69) 69
liver cancer (68) 68
abdominal surgery (67) 67
adolescent (67) 67
endoscopy (67) 67
biological response modifiers (66) 66
peripheral vascular disease (66) 66
drug therapy, combination (65) 65
risk-factors (63) 63
fibrosis (62) 62
antiviral agents - administration & dosage (60) 60
prevalence (60) 60
stomach neoplasms - pathology (60) 60
colorectal neoplasms - pathology (58) 58
hepacivirus - drug effects (58) 58
hepatitis c, chronic - virology (58) 58
biopsy (56) 56
hepatoma (56) 56
recurrence (56) 56
research (56) 56
endothelial function (54) 54
immunohistochemistry (52) 52
medical research (52) 52
patients (52) 52
polymerase chain reaction (52) 52
replication (52) 52
universities and colleges (52) 52
colorectal cancer (51) 51
interferon-alpha - therapeutic use (51) 51
atherosclerosis (50) 50
predictive value of tests (50) 50
survival (50) 50
pharmacology & pharmacy (49) 49
medicine, experimental (48) 48
sensitivity and specificity (48) 48
case-control studies (47) 47
hcv (46) 46
japan - epidemiology (46) 46
cell line, tumor (45) 45
gene expression (45) 45
hepatitis b (45) 45
prospective studies (45) 45
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BMC gastroenterology, 11/2014, Volume 14, p. 203
The incidence of early-onset (under 50 years of age) colorectal cancer (CRC) in the Vietnamese has been reported to be quite higher than that in the Japanese.... 
Microsatellite Instability | Colorectal Neoplasms - genetics | Humans | Japan | Middle Aged | Asian Continental Ancestry Group - genetics | Male | Vietnam | DNA, Mitochondrial - genetics | Aged, 80 and over | Adult | Female | Aged | Mutation | Colorectal Neoplasms - pathology | Genes, ras - genetics
Journal Article
Journal Article
by Kawashima, Minae and Hitomi, Yuki and Aiba, Yoshihiro and Nishida, Nao and Kojima, Kaname and Kawai, Yosuke and Nakamura, Hitomi and Tanaka, Atsushi and Zeniya, Mikio and Hashimoto, Etsuko and Ohira, Hiromasa and Yamamoto, Kazuhide and Abe, Masanori and Nakao, Kazuhiko and Yamagiwa, Satoshi and Kaneko, Shuichi and Honda, Masao and Umemura, Takeji and Ichida, Takafumi and Seike, Masataka and Sakisaka, Shotaro and Harada, Masaru and Yokosuka, Osamu and Ueno, Yoshiyuki and Senju, Michio and Kanda, Tatsuo and Shibata, Hidetaka and Himoto, Takashi and Murata, Kazumoto and Miyake, Yasuhiro and Ebinuma, Hirotoshi and Taniai, Makiko and Joshita, Satoru and Nikami, Toshiki and Ota, Hajime and Kouno, Hiroshi and Kouno, Hirotaka and Nakamuta, Makoto and Fukushima, Nobuyoshi and Kohjima, Motoyuki and Komatsu, Tatsuji and Komeda, Toshiki and Ohara, Yukio and Muro, Toyokichi and Yamashita, Tsutomu and Yoshizawa, Kaname and Nakamura, Yoko and Shimada, Masaaki and Hirashima, Noboru and Sugi, Kazuhiro and Ario, Keisuke and Takesaki, Eiichi and Naganuma, Atsushi and Mano, Hiroshi and Yamashita, Haruhiro and Matsushita, Kouki and Yamauchi, Kazuhiko and Makita, Fujio and Nishimura, Hideo and Furuta, Kiyoshi and Takahashi, Naohiro and Kikuchi, Masahiro and Masaki, Naohiko and Tanaka, Tomohiro and Tamura, Sumito and Mori, Akira and Yagi, Shintaro and Shirabe, Ken and Komori, Atsumasa and Migita, Kiyoshi and Ito, Masahiro and Nagaoka, Shinya and Abiru, Seigo and Yatsuhashi, Hiroshi and Yasunami, Michio and Shimoda, Shinji and Harada, Kenichi and Egawa, Hiroto and Maehara, Yoshihiko and Uemoto, Shinji and Kokudo, Norihiro and Takikawa, Hajime and Ishibashi, Hiromi and Chayama, Kazuaki and Mizokami, Masashi and Nagasaki, Masao and Tokunaga, Katsushi and Nakamura, Minoru
Human Molecular Genetics, ISSN 0964-6906, 2017, Volume 26, Issue 3, pp. 650 - 659
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 02/2018, Volume 62, Issue 2
Glecaprevir and pibrentasvir are hepatitis C virus (HCV) pangenotypic inhibitors targeting NS3/4A protease and NS5A, respectively. This once-daily, fixed-dose... 
Pibrentasvir | NS5A inhibitor | HCV | Glecaprevir | Protease inhibitors | SOFOSBUVIR | MICROBIOLOGY | OPEN-LABEL | RIBAVIRIN | GENOTYPE 1 | IN-VITRO | pibrentasvir | NS5A | protease inhibitors | HCV GENOTYPE | ANTIVIRAL ACTIVITY | PHARMACOLOGY & PHARMACY | DACLATASVIR | INHIBITOR | glecaprevir
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 4/2018, Volume 53, Issue 4, pp. 566 - 575
Once-daily, orally administered, co-formulated glecaprevir (NS3/4A protease inhibitor) and pibrentasvir (NS5A inhibitor) (G/P) demonstrated pangenotypic... 
Pibrentasvir | Cirrhosis | Medicine & Public Health | Glecaprevir | Colorectal Surgery | Hepatology | Gastroenterology | Renal failure | Abdominal Surgery | Special population | Surgical Oncology | PLUS RIBAVIRIN | SOFOSBUVIR | CHRONIC HEPATITIS-C | OPEN-LABEL | TREATMENT-NAIVE | PHASE-3 TRIAL | DACLATASVIR | GASTROENTEROLOGY & HEPATOLOGY | BURDEN | EPIDEMIOLOGY | Quinoxalines - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Young Adult | Treatment Failure | Adult | Female | Renal Insufficiency - complications | Benzimidazoles - adverse effects | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Quinoxalines - therapeutic use | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Aged | Sustained Virologic Response | Medical research | Protease inhibitors | Proteases | Analysis | Medicine, Experimental | Genetic aspects | Biological response modifiers | Hepatitis C virus | Health aspects | Liver cirrhosis | Kidneys | Hemodialysis | Oral administration | Chronic infection | Interferon | Ribonucleic acid--RNA | Patients | Glomerular filtration rate | Kidney transplantation | Original —Liver, Pancreas, and Biliary Tract
Journal Article
Hepatology, ISSN 0270-9139, 02/2018, Volume 67, Issue 2, pp. 505 - 513
Glecaprevir (nonstructural protein 3/4A protease inhibitor) and pibrentasvir (nonstructural protein 5A inhibitor) (G/P), a coformulated once‐daily, all oral,... 
ASIA | SOFOSBUVIR | CIRRHOSIS | PHASE-3 TRIAL | PREVALENCE | RIBAVIRIN | GASTROENTEROLOGY & HEPATOLOGY | BURDEN | Cirrhosis | Antiretroviral drugs | Hepatitis | Chronic infection | Infections | Interferon | Safety | Hepatitis C | Patients | Ribavirin | Genotypes | Original
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 4/2018, Volume 53, Issue 4, pp. 557 - 565
The once-daily, all oral, RBV-free, pangenotypic direct-acting anti-viral regimen consisting of co-formulated NS3/4A protease inhibitor glecaprevir and NS5A... 
Medicine & Public Health | Colorectal Surgery | Hepatology | Gastroenterology | Abdominal Surgery | Glecaprevir/pibrentasvir | Hepatitis C virus | Surgical Oncology | Direct-acting antivirals | ASIA | PHASE-3 TRIAL | RIBAVIRIN | COMPENSATED CIRRHOSIS | COMBINATION | GASTROENTEROLOGY & HEPATOLOGY | BURDEN | EPIDEMIOLOGY | Quinoxalines - adverse effects | Anilides - therapeutic use | Age Distribution | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Quinoxalines - blood | Sulfonamides - blood | Aged, 80 and over | Ritonavir - therapeutic use | Adult | Female | Benzimidazoles - adverse effects | Drug Therapy, Combination | Benzimidazoles - blood | Benzimidazoles - therapeutic use | Quinoxalines - therapeutic use | Hepacivirus - isolation & purification | Liver Cirrhosis - drug therapy | Drug Administration Schedule | Antiviral Agents - blood | Antiviral Agents - therapeutic use | Viral Nonstructural Proteins - genetics | Liver Cirrhosis - blood | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Macrocyclic Compounds - therapeutic use | Liver Cirrhosis - virology | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Aged | Sustained Virologic Response | Carbamates - therapeutic use | Drug Combinations | Virus diseases | Medical research | Protease inhibitors | Proteases | Medicine, Experimental | Genetic aspects | Health aspects | Liver cirrhosis | Cirrhosis | Antiviral agents | Ritonavir | Chronic infection | Proteinase inhibitors | Hepatitis C | Patients | Genotypes | Glecaprevir | pibrentasvir | Original —Liver, Pancreas, and Biliary Tract
Journal Article
Nature Genetics, ISSN 1061-4036, 07/2012, Volume 44, Issue 7, pp. 760 - 764
Journal Article
Journal Article
Journal Article